

HAEMONETICS CORP  
Form 8-K  
March 24, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 24, 2014

HAEMONETICS CORPORATION  
(Exact name of registrant as specified in its charter)

|  |  |   |
|--|--|---|
| Massachusetts<br>(State or other jurisdiction<br>of incorporation) | 1-14041<br>(Commission<br>File Number) | 04-2882273<br>(I.R.S. Employer<br>Identification No.) |
|--|--|---|

|   |                     |
|---|---------------------|
| 400 Wood Road, Braintree MA<br>(Address of principal executive offices) | 02184<br>(Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events

On March 24, 2014, Haemonetics Corporation issued a press release with an update on The American Red Cross whole blood tender. The press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION  
(Registrant)

Date: March 24, 2014

By: /s/ Christopher Lindop  
Christopher Lindop, Vice President  
and Chief Financial Officer